The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010
Open accessAbstract
IMPORTANCE: Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them. OBJECTIVE: To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality. DESIGN, SETTING, AND PARTICIPANTS: A time-series analysis was conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included. EXPOSURES: Presence of a law establishing a medical cannabis program in the state. MAIN OUTCOMES AND MEASURES: Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate. RESULTS: Three states (California, Oregon, and Washington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate (95% CI, -37.5% to -9.5%; P = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (-19.9%; 95% CI, -30.6% to -7.7%; P = .002), year 2 (-25.2%; 95% CI, -40.6% to -5.9%; P = .01), year 3 (-23.6%; 95% CI, -41.1% to -1.0%; P = .04), year 4 (-20.2%; 95% CI, -33.6% to -4.0%; P = .02), year 5 (-33.7%; 95% CI, -50.9% to -10.4%; P = .008), and year 6 (-33.3%; 95% CI, -44.7% to -19.6%; P < .001). In secondary analyses, the findings remained similar. CONCLUSIONS AND RELEVANCE: Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse health effects of marijuana use.
Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1402309 · Cited by 2,774
The Economic Costs of Pain in the United States
Gaskin, D. J., & Richard, P. (2012) · The Journal of Pain · doi:10.1016/j.jpain.2012.03.009 · Cited by 2,359
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
Paulozzi, L. J., Jones, C. M., Mack, K. A., & Rudd, R. A. (2011) · PubMed · Cited by 1,529
Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths
Bohnert, A. S. B. (2011) · JAMA · doi:10.1001/jama.2011.370 · Cited by 1,509
Opioid Prescriptions for Chronic Pain and Overdose: A Cohort Study
Dunn, K. M., Saunders, K. W., Rutter, C. M., Banta-Green, C. J., Merrill, J. O., Sullivan, M. D., Weisner, C. M., Silverberg, M. J., Campbell, C. I., Psaty, B. M., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00006 · Cited by 1,255
Tanda, G., Pontieri, F. E., & Chiara, G. D. (1997) · Science · doi:10.1126/science.276.5321.2048 · Cited by 1,080
Pharmacology and effects of cannabis: A brief review
Ashton, C. H. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.2.101 · Cited by 934
Pharmaceutical Overdose Deaths, United States, 2010
Jones, C. M., Mack, K. A., & Paulozzi, L. J. (2013) · JAMA · doi:10.1001/jama.2013.272 · Cited by 678
Escalation of Drug Use in Early-Onset Cannabis Users vs Co-twin Controls
Lynskey, M. T., Heath, A. C., Bucholz, K. K., Slutske, W. S., Madden, P. A. F., Nelson, E. C., Statham, D. J., & Martin, N. G. (2003) · JAMA · doi:10.1001/jama.289.4.427 · Cited by 649
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
(2011) · PubMed · Cited by 640
Early onset cannabis use and psychosocial adjustment in young adults
Fergusson, D. M., & Horwood, L. J. (1997) · Addiction · doi:10.1046/j.1360-0443.1997.9232794.x · Cited by 494
CDC grand rounds: prescription drug overdoses - a U.S. epidemic.
(2012) · PubMed · Cited by 494
Cerdá, M., Wall, M., Keyes, K. M., Galea, S., & Hasin, D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.06.011 · Cited by 490
Patterns of drug use from adolescence to young adulthood: III. Predictors of progression.
Yamaguchi, K., & Kandel, D. B. (1984) · American Journal of Public Health · doi:10.2105/ajph.74.7.673 · Cited by 439
Marijuana and medicine: assessing the science base
(1999) · Choice Reviews Online · doi:10.5860/choice.37-2206 · Cited by 410
Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials
Lynch, M. E., & Campbell, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03970.x · Cited by 397
Effect of Abuse-Deterrent Formulation of OxyContin
Cicero, T. J., Ellis, M. S., & Surratt, H. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1204141 · Cited by 336
Cannabinoid–Opioid Interaction in Chronic Pain
Abrams, D. I., Couey, P., Shade, S. B., Kelly, M. E., & Benowitz, N. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.188 · Cited by 319
Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000–2010
Daubresse, M., Chang, H.-Y., Yu, Y., Viswanathan, S., Shah, N. D., Stafford, R. S., Kruszewski, S. P., & Alexander, G. C. (2013) · Medical Care · doi:10.1097/mlr.0b013e3182a95d86 · Cited by 318
Unick, G. J., Rosenblum, D., Mars, S., & Ciccarone, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054496 · Cited by 255
Pharmacological actions and therapeutic uses of cannabis and cannabinoids
Kumar, R. N., Chambers, W. A., & Pertwee, R. G. (2001) · Anaesthesia · doi:10.1046/j.1365-2044.2001.02269.x · Cited by 218
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal
Scavone, J. L., Sterling, R. C., & Van Bockstaele, E. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.034 · Cited by 209
Does Marijuana Use Cause the Use of Other Drugs?
Kandel, D. B. (2003) · JAMA · doi:10.1001/jama.289.4.482 · Cited by 166
Sidney, S., Beck, J. E., Tekawa, I. S., Quesenberry, C. P., & FRIEDMAN, G. D. (1997) · American Journal of Public Health · doi:10.2105/ajph.87.4.585 · Cited by 147
Marijuana Liberalization Policies: Why We Can't Learn Much from Policy Still in Motion
Pacula, R. L., & Sevigny, E. L. (2013) · Journal of Policy Analysis and Management · doi:10.1002/pam.21726 · Cited by 138
Peavy, K. M., Banta‐Green, C. J., Kingston, S., Hanrahan, M. T., Merrill, J. O., & Coffin, P. O. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.704591 · Cited by 134
Fiellin, L. E., Tetrault, J. M., Becker, W. C., Fiellin, D. A., & Hoff, R. A. (2012) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2012.06.010 · Cited by 118
Impact of Cannabis Use during Stabilization on Methadone Maintenance Treatment
Scavone, J. L., Sterling, R. C., Weinstein, S. P., & Bockstaele, E. J. V. (2013) · American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12044.x · Cited by 86
Khosla, N., Juon, H. S., Kirk, G. D., Astemborski, J. A., & Mehta, S. H. (2011) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.07.046 · Cited by 63
Cannabis Reduces Opioid Dose in the Treatment of Chronic Non-Cancer Pain
Lynch, M. E., & Clark, A. J. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00142-8 · Cited by 56
Low efficacy of non-opioid drugs in opioid withdrawal symptoms
Hermann, D., Klages, E., Welzel, H., Mann, K. F., & Croissant, B. (2005) · Addiction Biology · doi:10.1080/13556210500123514 · Cited by 24
Cited by
Designing Difference in Difference Studies: Best Practices for Public Health Policy Research
Wing, C., Simon, K., & Bello-Gomez, R. A. (2018) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040617-013507 · Cited by 1,470
Practical considerations in medical cannabis administration and dosing
MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663
Public health and international drug policy
Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00619-x · Cited by 641
Prevention and Treatment of Opioid Misuse and Addiction: A Review
Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3126 · Cited by 596
US epidemiology of cannabis use and associated problems
Hasin, D. S. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.198 · Cited by 578
Metadata
- Authors
- Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2014-10-01
- Volume
- 174
- Issue
- 10
- Pages
- 1668
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2123439904
- Cited by
- 695
- References
- 31
- FWCI
- 49.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.